ANVS
Annovis Bio Inc (ANVS)
Healthcare • NYSE • $2.28+0.88%
- Symbol
- ANVS
- Exchange
- NYSE
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $2.28
- Daily Change
- +0.88%
- Market Cap
- $78.99M
- Trailing P/E
- N/A
- Forward P/E
- -1.68
- 52W High
- $5.50
- 52W Low
- $1.48
- Analyst Target
- $12.50
- Dividend Yield
- N/A
- Beta
- 1.26
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia. Annovis Bio, Inc. was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.
Company websiteResearch ANVS on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.